This is third in a series. The first piece asked whether Philips is building an ecosystem or borrowing its language. The second asked what architecture a genuine system-shaping role requires.

This piece puts Philips, Siemens Healthineers, and GE HealthCare through the same nine-dimension IIBE assessment side by side — asking what a like-for-like architectural read reveals that a quarterly results comparison cannot.

One critical issue to ask : This looks beyond comparing scores at the harder structural question underneath as we compare: has any of them actually built an ecosystem, or are all three still running sophisticated versions of the same bilateral sell?

This is about a 15 minute read.

In this nine IIBE dimensions we look across rivals to see differences and opportunities offering competitive positioning and opportunity points and where it places Philips in its approaches.

Each scores a company 0–10 on a specific architectural capability — not performance, not intent as stated in a press release, but what the organisation has actually built. The score is not a financial rating — it’s a judgment about ecosystem readiness, built by weighing multiple public inputs against the framework’s diagnostic criteria

Applied consistently across Philips, Siemens Healthineers, and GE HealthCare, the comparison stops being about who is winning this quarter and starts being about who, if anyone, has genuinely escaped the bilateral logic all three are competing inside.

The Scores, Side by Side

Philips appears twice in this table deliberately. The first column is what the nine dimensions produce from public information alone — results, Capital Markets Day positioning, press releases, the same kind of material available on any of the three companies. The second is the same assessment revised after weighing qualitative organisational intelligence on Philips’ actual investment behaviour — signals not available, and not attempted, for Healthineers or GE HealthCare.

The two Philips columns are not two independent measurements. They are the same company read at two different depths of information, and only one of those depths has been applied consistently across all four columns. That asymmetry is worth holding in mind: the Philips-specific finding is more informed than the cross-company comparison itself.

* The revised Philips column is based on qualitative signals that do not appear in any public filing — these are signals, some consistent with the CEO’s own public acknowledgment that slower growth leaves less room to invest in innovation. They are a diagnostic hypothesis serious enough to act on, not an established fact — and the reader should weigh the revised column accordingly against the more conventionally-sourced public read alongside it.

They rest on access and judgment built over time, not on a citable record, the same way they would with any analyst or journalist working sources rather than only filings as a diagnostic hypothesis serious enough to act on, not as an established fact, This includes signals on stalled pilot projects with no clarity on next steps, budget and headcount reductions or shifts within teams in specific innovation functions. These signals speak to ambition and risk appetite, but they are not independently checkable by a reader.

The nine dimension scores that shift upward on the public assessment as specific for Philips can be summarised briefly on where the present internal assessment might be to where it is “projected” in the public understandings.

Clarify identified gaps as building clear intent

It is these identified “gaps” that need articulating specifically to narrow them in my evaluations otherwise the lower score stands.

Dimension 1 — Strategic intent: 5 to 7. Taking Public language as ecosystem-adjacent and genuine in its ambition. Jakobs’ Davos positioning, the connected care narrative, the platform innovation framing all read as real strategic intent from the outside. Is It?

Dimension 2 — Value architecture: 5 to 6. EMaaS, the AdventHealth partnership, the enterprise service model transition all represent genuine value architecture movement visible publicly. Will they build this out?

Dimension 3 — Partner orchestration: 3 to 6. From the outside the Digital Connected Care Coalition, the hospital partnerships, and the AWS collaboration read as a developing orchestration capacity rather than purely bilateral management. How will these evolve?

Dimension 6 — Innovation architecture: 3 to 6. The BlueSeal, Rembra, Verida innovations and the “no product without AI” mandate read publicly as a maintained innovation posture rather than a structurally inhibited one. This needs clarifying

Dimension 7 — Resilience: 5 to 6. The public financial recovery narrative — margins expanding, order intake growing, balance sheet rebuilt — reads as genuine resilience improvement. This is where Philips have placed the mephasis, 2026 quartely results will determine this

Dimension 9 — Dynamic orchestration: 3 to 5. From outside there is no visible evidence of restriction — the adaptive capacity gap looks like a design gap rather than a deliberate inhibition. This is discussed further in this post.

Six Major Things the Table Reveals

First — on the public read alone, Philips looks broadly competitive with both rivals.

65 against 68 and 71 is a gap, not a chasm. On several dimensions the public-only Philips score matches or nearly matches Healthineers outright — governance, data intelligence, moat architecture. Anyone assessing Philips purely from what it says and reports would reasonably conclude it is in the same tier as its rivals, running a few points behind. That conclusion would not be unreasonable. It would also be incomplete.

Second — the ten-point revision does not fall evenly. It concentrates precisely where it should.

Partner orchestration and innovation architecture each drop three full points — the two largest single-dimension movements in the table. Data intelligence drops one point despite the “no product without AI” mandate remaining genuine, because owning the mandate is not the same as owning the infrastructure behind it. Governance, resilience, and moat architecture each move by only a single point, because those dimensions rest on things already built — compliance systems, installed base, balance sheet — rather than on what gets funded next. The revision lands exactly where an extraction-first capital posture would be expected to show up first. That is itself a diagnostic signal.

Third — Dimension 9 is the one place where both Philips readings already agreed.

Dynamic orchestration scored lowest of all nine dimensions in the public-only assessment — 5/10, a full point below the next-lowest dimension. No insider intelligence was needed to reach that conclusion. The single dimension every company in this comparison is weakest on is also the one where Philips’ own public conduct, read without any internal intelligence at all, already pointed to the same conclusion the deeper read confirmed. That is a useful piece of corroboration for the revision comparision as a whole.

Fourth — the gap between Philips and its rivals is real but concentrated, not uniform.

On governance and trust architecture, all three cluster within a single point. The dimensions where the gap widens sharply are innovation architecture — 3 versus 6 and 8 — and data intelligence — 6 versus 8 and 8. Precisely the two dimensions that require sustained capital investment in experimentation and owned intelligence infrastructure. The gap is not that Philips lacks ecosystem vocabulary or governance discipline. The gap is specifically where a restrained internal investment posture would be expected to show up first.

Fifth — GE HealthCare’s advantage is structurally different from Siemens Healthineers’, even though their overall scores sit close.

Healthineers’ strength is asset-based — the imaging data estate, the Varian oncology position, moat architecture built over decades. GE’s strength is closer to genuine platform design — the Edison Developer Programme brings in third-party AI developers and academic institutions under something closer to shared infrastructure than either rival has built. GE scores highest on partner orchestration precisely because Edison is doing something the other two are not: letting outside actors build on its rails rather than simply selling into a customer base. That distinction matters for understanding which competitive gaps are closeable through investment and which require a different architectural logic entirely. This gives GE a real edge if they take this into a fully build ecosystem approach.

Sixth — and this is the finding that matters most — every company scores in the same narrow band on Dimension 9.

Dynamic Orchestration and Evolution Capacity: 3 to 5 across all three. That is not a coincidence. It is the finding that validates the whole diagnostic exercise rather than simply describing Philips’ position within it.

Why Dimension 9 Is the Finding, Not a Footnote

Dynamic orchestration asks whether a company has built the sensing-and-response mechanism that lets an ecosystem actually evolve — a function that notices what emerges from a partner network, interprets it, and routes it back into how the architecture operates. In the IIBE framework this is called the Living Bridge. No company evaluated here has one.

That includes GE HealthCare, which has built the most platform-mature architecture of the three. Edison aggregates data across modalities and vendors, hosts a genuine developer ecosystem, and produced roughly forty third-party innovations in the past year through its accelerator model. And it still tops out at 5/10 on dynamic orchestration — because Edison optimises the relationship between GE and each partner individually. It does not yet let partners create value for each other in ways that compound back into the network without GE mediating every interaction.

It includes Siemens Healthineers — four years into the Varian integration — where the internal language is still education, co-location, and relationship-building rather than co-created value at the network level. And it includes Philips, scoring lowest of the three — not for lack of the underlying design skill, which the Digital Connected Care Coalition already demonstrates, but because that skill has never been pointed at the commercial architecture where dynamic orchestration would actually need to operate.

This is the point worth making plainly. The two companies with the deepest data estates and the largest innovation budgets in the sector have not solved this either. If capital and data alone were sufficient, GE’s $5.1 billion innovation commitment and Healthineers’ imaging data moat would have produced it by now. They have not — because dynamic orchestration is not a spending problem. It is a design problem. And none of the three has yet chosen to design for it specifically.

That is the strongest available evidence that the gap this series has been describing at Philips is not just a Philips ‘issue’. It is a category-wide architectural absence that happens to be more acute at Philips because of where its capital allocation currently sits.

The Bilateral Trap — and Why It Does Not Move for Shareholders

Every large deal named across all three companies this year is structurally the same thing. Healthineers with Cleveland Clinic and Vanderbilt. GE with Sutter Health and Catholic Health. Philips with WellSpan and the Poland platform agreement. Each a large, multi-year, bilateral contract. Each genuinely valuable commercially. None of it evidence of ecosystem architecture — because in every case value still flows through the vendor, negotiated and priced deal by deal, rather than through a governed network where partners build value independently of the vendor’s direct involvement.

That pattern persists for a reason that has nothing to do with any of the three lacking vision. It has everything to do with what public markets currently reward. Ecosystem architecture requires multi-year investment in infrastructure whose payoff is genuinely uncertain and shows up on nobody’s quarterly guidance. Bilateral deals show up immediately — in orders, in backlog, in the numbers an analyst can model.

The market has already chosen for them. The result is a structural trap: strong volume, compressing underlying margin, and every vendor’s rational response to margin pressure being to protect this quarter rather than fund next decade’s architecture. It is precisely the dynamic that keeps all three capped at Dimension 9 — and the one that will continue to do so until one of them makes the architectural decision to break out of it first.

All three companies could hit every number analysts are modelling for the next three years and still be exactly where they are today on the one dimension that determines whether any of them stops competing on price- they are all stuck in a bilaterial trap as they begin the “race to the bottom”.

Siemens AG’s Counter-Evidence: Structural Courage Exists

It is worth being fair to what the Siemens Group has shown it is capable of — because it complicates any argument that public markets simply forbid bold structural change.

Siemens AG has committed to fully deconsolidating Healthineers — not trimming a stake, but distributing shares directly to its own shareholders and exiting the business entirely, with a vote scheduled for the February 2027 AGM. This follows the earlier separation of Siemens Energy, which endured genuinely difficult years before recovering on the back of surging grid and gas demand. This is a group that has demonstrated real willingness to make structurally uncomfortable portfolio decisions and absorb the short-term cost.

Healthineers itself is separately weighing a carve-out of its Diagnostics unit alongside a leadership refresh — a new EMEA head, an incoming CHRO, and the arrival of Martin Stumpe as CTO from Google Brain with an explicit mandate to expand AI capabilities dramatically. Whether that combination is specifically intended to put data architecture more centrally in the business is not confirmed by the public record. It is a reasonable question to hold open.

What the Siemens picture shows is that boldness toward architecture is possible within the same ownership and market constraints that appear to prevent it elsewhere.

What These Nine Dimensions Validates — and What It Does Not

Applying the same nine dimensions across three comparable companies does something a single-company diagnostic cannot: it separates what is specific to Philips from what is structural to the sector.

The gap in innovation architecture and data intelligence is real and specific to Philips’ current capital allocation — that finding holds up under comparison rather than dissolving. But the absence of dynamic orchestration is not a Philips finding. It is a category finding, present at identical severity in the two companies best resourced to have solved it, who have plainly not.

That is the genuine validation for a diagnostic-first approach to this sector. Not that it proves any one company is behind, but that it shows precisely where conventional performance metrics — margin, order growth, capital committed — run out of explanatory power, and where the structural question takes over.

Specifically for Philips for its future

For Philips you have to ask If Philips’ strategic ambition is to become a system shaper in European MedTech and beyond, then it needs to preserve certain options: shared-governance capability, interoperable interfaces, partner incentives, clinical-data rights and sustained experimentation.

If, instead, its ambition is to be a focused, high-quality technology supplier and selective partner, then some of the apparent option closure needed to be made may be deliberate. That would be a different strategic choice, and it may be worth making that choice explicit.

Making this distinction clearer could pre-empt the natural counterargument that tighter capital allocation, selected partnerships and reduced experimentation are simply sensible sequencing after Respironics. It would also sharpen the board question: not whether Philips is “wrong,” but whether its capital allocation, governance and architecture are consistent with the role it genuinely intends to play.

The final piece in this series follows and applies the Optionality and Volatility lens to Philips — examining what strategic options are open, which are closing, and where the volatility the organisation faces is most acutely unhedged. It introduces a methodological distinction that takes the diagnostic one level further: two scores, one diagnostic instrument, and why the gap between them is the finding that existing conventional assessment cannot reach.

Paul Hobcraft is the creator of the Intelligent Integrated Business Ecosystem (IIBE) framework, working with large industrial enterprises and institutional bodies on ecosystem architecture, governance, and orchestration design.

paul4innovating.com  ·  ecosystems4innovation.com

·  MedTech Ecosystem Architecture Series